Physician profile
Scott Lieberman
NPI 1871644781
$3,049.84
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,189 · 2020: $268 · 2021: $580 · 2022: $12.89.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $410.10 | 2019-2021 | |
| Pfizer INC. | $362.22 | 2019-2021 | |
| Glaxosmithkline, LLC. | $334.95 | 2019-2021 | |
| Lilly USA, LLC | $286.31 | 2019-2021 | |
| Novo Nordisk INC | $276.39 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.02 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $157.42 | 2019-2021 | |
| Astellas Pharma US INC | $141.61 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $125.02 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.95 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $114.74 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $102.02 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.78 | 2019-2021 | |
| Amarin Pharma, INC. | $39.50 | 2019-2020 | |
| Abbvie INC. | $38.80 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $35.20 | 2019 | |
| Ibsa Pharma INC. | $31.71 | 2020-2021 | |
| Daiichi Sankyo INC. | $30.15 | 2019 | |
| Ironshore Pharmaceuticals INC. | $24.08 | 2020 | |
| Eisai INC. | $18.71 | 2021 | |
| Genentech USA, INC. | $18.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.05 | 2019 | |
| Shire North American Group INC | $16.68 | 2019 | |
| Amgen INC. | $16.62 | 2019 | |
| Allergan, INC. | $13.56 | 2019 | |
| Abbott Laboratories | $13.18 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $12.40 | 2019 | |
| Insmed, INC. | $12.34 | 2020 | |
| Hikma Pharmaceuticals USA | $11.31 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Lieberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.